Pfizer aims to fix EU worries about Wyeth deal; Roche offers lower-cost Tamiflu for poor countries;

> Pfizer has offered remedies aimed at tackling concerns that its $68 billion planned takeover of rival Wyeth may be anti-competitive, the European Commission said on Tuesday. Report

> Roche will stockpile Tamiflu at a reduced price for developing countries, ready for use if and when needed, the company said. Roche release

> Astellas Pharma submitted test data on Flomax to FDA, hoping to win the right to extend exclusivity on the drug in the U.S. through until April; now its patent is scheduled to expire in October. Report

> Teva Pharmaceutical Industries got the FDA nod for its version of the Johnson & Johnson contraceptive pill Ortho Tri-Cyclen Lo. Report

> Patients who received a bioengineered protein sold by Medtronic or Stryker during spinal fusion procedures to correct neck pain had far more complications than patients who did not, a study showed. Report

Biotech News

> Israel's Optimata and Teva Pharmaceutical Industries have teamed up to develop cancer drugs. The two say they will "efficiently rescue" failed advanced stage clinical trials. Report

> South San Francisco-based Catalyst Biosciences and Wyeth Pharmaceuticals announced that the companies have entered into a worldwide collaboration valued at potentially more than $500M for the discovery, development and commercialization of recombinant Factor VIIa products for patients with hemophilia and other bleeding conditions. Report

> San Francisco-based Hyperion Therapeutics has raised a whopping $60 million in a Series C financing round. New investors Bay City Capital and Panorama Capital co-led the financing, while existing investors Highland Capital Partners, NEA, and Sofinnova Ventures also participated. Report

> Former Genentech CFO David Ebersman has found a new home as the first CFO of Facebook. The biotech veteran, who spent 15 years with Genentech, was promoted as the company's CFO in 2006. Report

> Cell Genesys has put an end to its financial woes through a $38 million merger with BioSante. The two companies will merge in an all-stock deal; BioSante will be the surviving company. Report

Manufacturing News

> The recent UPS supply chain survey, which found that 36 percent of pharmaceutical and biotech respondents say they are "highly concerned" about product tampering or counterfeiting--fourth place among choices provided--is likely due to the fact that the bulk of the problem still resides in under-developed countries, says Bill Hook, UPS VP for healthcare logistics global strategy. "It came in a little higher than I expected," he says. Report

> As the first U.S. doses of government-contracted H1N1 swine flu vaccine were produced last week-via egg-less insect cell technology-the FDA reminds the public to be wary of Internet sites and other promotions for products that claim to diagnose, prevent, treat or cure the virus. Report

> The decontamination of a Boston-area Genzyme plant due to a virus in a bioreactor will take longer than expected, the company says, extending the rationing of the two drugs made there. Report

> Continued violations of good manufacturing practices have led to the seizure of 33 medications and drug ingredients at plants in Michigan, the FDA says. Report

> A single-use benchtop bioreactor ready to use out of the box is expected to launch next month, according to Massachusetts manufacturer Millipore. The 3-liter CellReady Bioreactor is part of the company's Mobius line. Report

And Finally... Buenos Aires, hit hard by the H1N1 "swine" flu, declared a health emergency and said it will add two weeks to school holidays in July. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.